课题基金 / 基金详情

Optimal Generation and Characterization of iPS Cell Lines from Healthy and ADHD S

Optimal Generation and Characterization of iPS Cell Lines from Healthy and ADHD S
健康和多动症 iPS 细胞系的优化生成和表征
批准号:
7939927
负责人:
Kwang-Soo Kim
金额:
$23.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-06-30

项目摘要

项目成果

Kwang-Soo Kim的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Understanding the molecular and cellular basis of neuropsychiatric disorders is one of the biggest and most significant challenges for the 21st century in neuroscience. Attention deficit hyperactivity disorder (ADHD) is the most common childhood psychiatric disorder and is characterized by inattention, distractibility, impulsivity, and/or the presence of hyperactivity. Numerous laboratories have shown that ADHD is highly heritable (approximate heritability is 0.8) although environmental factors also importantly influence its pathogenesis. To further advance our understanding of ADHD's molecular pathogenesis it is desirable to establish multipotent stem cells with the genetic backgrounds of ADHD and healthy subjects for biological and molecular comparisons. In 2006, Shinya Yamanaka and his colleagues published their groundbreaking work showing that pluripotent stem cells, so called "induced pluripotent stem (iPS) cells, can be generated from somatic cells by retroviral transduction of four transcription factors (i.e., Oct4, Sox2, Klf4 and c-Myc). Strikingly, several groups, including Yamamaka's, soon demonstrated that human iPS cells could be generated by similar methods. Although this iPS technology is still at an early stage and needs further development, based on these pioneering studies and our own preliminary results, we hypothesize that potential pathogenic mechanisms of ADHD can be investigated by generating ADHD-specific iPS cells and by using in vitro differentiation studies, comparing them with those of iPS cells derived from healthy subjects. Toward this long-term goal, during the R21 phase of the project, we propose (1) to establish multiple iPS lines from healthy and ADHD subjects, (2) to validate iPS cell lines by cellular, molecular, and differentiation analyses, and (3) to address whether the RAG1/RAG2 VDJ recombinase system can be used to screen and/or monitor human iPS cells' identity. In addition, during the R33 phase, we propose (1) to characterize the differentiation of individual iPS cell lines to expandable neural progenitors/precursors, (2) to characterize their differentiation to relevant neuronal subtypes such as dopaminergic and noradrenergic neurons, and (3) to compare cellular and differentiation properties of iPS cell lines from healthy and ADHD subjects for potential pathogenic mechanisms. PUBLIC HEALTH RELEVANCE: Recent groundbreaking work by Shinya Yamanaka and his colleagues introduced the "induced pluripotent stem (iPS) cell" technology, a tantalizing new method generating genetically matched pluripotent stem cells without embryo destruction. To fully utilize this revolutionary technique, we propose to further advance this method by establishing a human iPS screening/monitoring system, and to generate and characterize multiple iPS lines from healthy and ADHD subjects. This approach will advance the iPS cell technology and provide a platform for investigating the biological and molecular mechanisms underlying ADHD pathogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human iPSC-Based Personalized Cell Therapy of PD
  • 批准号:
    10678012
  • 项目类别:
  • 资助金额:
    $70.51万
  • 财政年份:
    2023
  • 负责人:
    Kwang-Soo Kim
  • 依托单位:
Crosstalk Between Nurr1 and Risk Factors of Parkinson's Disease and its Regulation by Nurr1's Ligands
  • 批准号:
    10677221
  • 项目类别:
  • 资助金额:
    $47.91万
  • 财政年份:
    2023
  • 负责人:
    Kwang-Soo Kim
  • 依托单位:
Crosstalk between Nurr1 and risk factors of Parkinson's disease and its regulation by Nurr1's ligands
  • 批准号:
    10592731
  • 项目类别:
  • 资助金额:
    $52.55万
  • 财政年份:
    2022
  • 负责人:
    Kwang-Soo Kim
  • 依托单位:
Functional Roles of Nurr1 in AD Related Pathophysiology
  • 批准号:
    8891618
  • 项目类别:
  • 资助金额:
    $23.7万
  • 财政年份:
    2015
  • 负责人:
    Kwang-Soo Kim
  • 依托单位:
海外基金